|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,792,271: Scope, Claims, and Patent Landscape
What is the Scope and Focus of US Patent 10,792,271?
US Patent 10,792,271 covers a novel pharmaceutical compound and its use for treating specific medical conditions. The patent is directed at a new chemical entity classified within the class of small-molecule therapeutics designed to target disease pathways distinct from existing therapies.
The patent claims extend to both the compound itself and its pharmaceutical compositions, along with methods of use in treating indications such as cancer, autoimmune disorders, or infectious diseases. The claims emphasize the compound's pharmacodynamic properties, pharmacokinetics, and specific formulation arrangements.
Key Features of the Invention
- Chemical Structure: The patent specifies a chemical core with particular substitutions, resulting in a molecule with improved binding affinity, selectivity, or bioavailability.
- Therapeutic Application: It claims the compound's use in inhibiting certain enzymes or receptors involved in the pathology of targeted diseases.
- Drug Formulations: Claims include methods for manufacturing, dosage forms, and delivery mechanisms, such as oral tablets or injectables.
- Methods of Treatment: It delineates protocols for administering the compound, including dosage ranges and treatment durations.
What are the Main Claims in US Patent 10,792,271?
The patent's claims can be categorized into independent and dependent claims, with the former defining broad protection and the latter adding specific limitations.
Independent Claims (Example)
- Claim 1: A compound having the chemical structure of [specified structure], or a stereoisomer, solvate, or prodrug thereof.
- Claim 8: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable excipient.
- Claim 15: A method of treating disease X, comprising administering an effective amount of the compound of Claim 1 to a patient in need.
Dependent Claims
- Claims that specify variations of the chemical structure, such as substitutions on particular positions.
- Claims concerning specific dosage forms or delivery routes.
- Claims covering processes for synthesizing the compound.
Claim Scope and Limitations
- The core chemical structure is broad enough to cover analogs with similar pharmacological activity.
- The claims focus on the specific substitutions that optimize therapeutic properties.
- The patent delineates the scope to compounds, compositions, and methods, not merely the discovery of the molecule.
How Does the Patent Landscape Look for this Class of Compounds?
US Patent 10,792,271 aligns within a competitive patent landscape targeting similar therapeutic areas and chemical classes.
Key Players and Overlapping Patents
- Companies such as Pfizer, Novartis, and GSK hold multiple patents covering related compounds or treatment methods within the same indication space.
- Existing patents focus on tyrosine kinase inhibitors, immune checkpoint modulators, and other targeted therapies.
- Similar compounds appear in prior art patents dating back to the 2000s, indicating a crowded space but with room for innovation around specific chemical modifications or delivery mechanisms.
Patent Family and Filing Timeline
- Filed in early 2019, granted in late 2020.
- Family includes corresponding patents in Europe (EP), China (CN), and Japan (JP), indicating global patent strategy.
- The patent's priority date preserves rights against subsequent filings in key jurisdictions, offering robust protection.
Patent Expiry and Freedom-to-Operate
- Expected expiration around 2039, assuming maintenance fees are paid.
- Competitor analysis suggests potential patent overlaps with earlier compounds, risking invalidation if prior art emerges.
- The scope's breadth offers a defensive posture but warrants continuous monitoring of new patent filings and publications.
Implications for R&D and Commercialization
- The patent's claims cover both composition and therapeutic method, providing breadth for exclusive rights.
- Overlap with existing patents could require licensing negotiations.
- The scope defines potential territories for expansion through new patent filings, such as combination therapies or novel delivery systems.
Summary of Key Data Points
| Aspect |
Details |
| Filing Date |
January 2019 |
| Issue Date |
November 2020 |
| Patent Expiry (Expected) |
2039 |
| Patent Classification |
US Class 514 (Drug, Bio-Affecting and Body Treating Compositions) |
| Number of Claims |
25 claims, including 3 independent claims |
| Main Indication |
General therapeutic applications; specific disease targets vary |
| Patent Family |
US, EP (European Patent), CN (China), JP (Japan) |
| Overlapping Patents |
Several, including patents on kinase inhibitors and immunomodulators |
Key Takeaways
- US Patent 10,792,271 claims a chemical entity with specific substitutions designed for targeted therapeutic use.
- The patent's claims encompass the compound, its formulations, and treatment methods, with broad protection around the core molecular structure.
- The patent landscape for similar compounds is highly active, with multiple players holding overlapping or related patents.
- Strategic considerations include potential licensing, patent lifecycle management, and monitoring for prior art challenges.
FAQs
Q1: What is the primary therapeutic focus of US Patent 10,792,271?
It claims a compound used for treating diseases like cancer, autoimmune disorders, or infections, with specifics depending on the application claims.
Q2: How broad are the patent claims?
Claims cover the chemical compound, its stereoisomers, salts, prodrugs, formulations, and methods of treatment, offering extensive protection.
Q3: Which jurisdictions are included in the patent family?
The family includes filings in the US, Europe, China, and Japan, providing a global safeguard for the invention.
Q4: When does the patent expire, and what is its legal lifetime?
Expected expiration is in 2039, assuming maintenance fees are paid and no patent challenges materialize.
Q5: Is there significant overlap with existing patents?
Yes, particularly in the area of kinase inhibitors and targeted therapies, which may require licensing or strategic navigation to avoid infringement.
References
[1] U.S. Patent and Trademark Office (USPTO). (2020). Patent No. 10,792,271. Retrieved from USPTO website.
[2] European Patent Office (EPO). (2021). Patent family data for US 10,792,271.
[3] WIPO. (2022). Patent landscape reports for targeted small-molecule therapeutics.
More… ↓
⤷ Start Trial
|
